Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related prod ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $128.8, ...
What Is Driving the Updated Illumina Price Target? Illumina's fair value estimate has been revised from about US$119.84 to ...
Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery.
Pharmaceutical Technology on MSN
JPM26: Illumina debuts billion cell atlas to drive AI-driven drug discovery
The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery.
Government-backed population genomics projects escalate demand, while AI and long-read sequencing tech enhance data analysis ...
Illumina shares edge down 3.5% in premarket trading after China placed restrictions on the company as it caught itself in the country's crosshairs in response to a developing trade war. Shares were ...
Jan 13 (Reuters) - Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help ...
The Illumina NovaSeq X adds to Agilus Diagnostics’ molecular testing portfolio through high-throughput sequencing and ...
Researchers are now exploring how to best extract and use saliva-derived DNA for long-read sequencing applications. Download ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results